Background & Objective: Some prostatic lesions contain small suspicious foci for prostatic carcinoma in which the morphological features are equivocal. Two immunohistochemical markers namely, cytokeratin 34 beta E12 (Ck34βE12) and α-Methylacyl-CoA racemase (AMACR), were evaluated in these lesions for a definitive diagnosis and avoiding misdiagnosis or overdiagnosis of prostatic...

The diagnosis of prostatic adenocarcinoma remains dependent on the recognition of basic haematoxylin and eosin criteria. The discovery of alpha-methylacyl CoA racemase/P504S (AMACR/P504S) overexpression in prostate cancer represents a triumph of high throughput microarray technology, and is a powerful demonstration of how this methodology can be used to facilitate the rapid development of diagn...

results a total number of 43 specimens were studied, from which 9 were obtained from patients with metastatic prostate cancer. the expression of five examined genes had no correlation with psa level and gleason score. the expression of amacr decreased in metastatic prostate cancer (p = 0.02). the expression of other genes showed no difference between metastatic and non-metastatic tumors (p > 0....

To investigate the potential relationship between sequence variants in the AMACR gene and prostate cancer risk in a Korean study cohort. We evaluated the association between 21 single nucleotide polymorphisms (SNPs) in the AMACR gene and prostate cancer risk as well as clinical characteristics (pathological stage and Gleason score) in Korean men (272 prostate cancer patients and 173 benign pros...

background and aims: p504s (amacr) is a mitochondrial enzyme expressed in renal cell carcinoma. some of immunohistochemical markers in renal cell tumors are independent prognostic factor and show relation with histologic grading. amacr expression increases with higher histological grading in different tumors; however, in rcc it is not obvious. in this study, we tried to investigate if any relat...

Since the discovery of alpha-methylacyl CoA racemase (AMACR) in prostate cancer in 2000, there have been a number of publications studying the diagnostic value of this enzyme. Although the role of this enzyme is still unknown, the application of AMACR immunohistochemistry in pathology practice has been increased sharply in the last few years. We are going to review the recent studies of the AMA...

Paneth cell-like neuroendocrine metaplasia of benign and cancerous prostate was described in 1992. Here, we note that P504S (AMACR), the cytoplasmic marker for prostate cancer used alone or in concert with basal cell markers, can be strongly reactive in benign prostatic acini with Paneth cell-like change.

PURPOSE Morphologic distinction among clear cell, papillary, and chromophobe types of renal cell carcinoma (RCC) can be difficult, as is the differential diagnosis between oncocytoma and RCC. Whether these renal tumors can be distinguished by their mRNA expression profile of a few selected genes was examined. EXPERIMENTAL DESIGN The expression of four genes in renal tumor was evaluated by qua...

PURPOSE To isolate human prostatic epithelial plasma membranes for the identification of cell surface proteins in the therapeutic targeting of cancer cells while permitting the retrieval of banked samples for clinical purposes. EXPERIMENTAL DESIGN Radical prostatectomies from 84 patients (median, 61 years; prostate-specific antigen, 5.9; 66% nonpalpable) were processed with alternate, mirror ...

The current study aimed to determine the incidence of various benign mimickers of prostatic adenocarcinoma most commonly encountered in a busy consultation practice. All prostate needle biopsies from the consult service of one of the authors were prospectively evaluated over a 7-month period. Only cases with foci where the contributor questioned malignancy and which upon expert review the entir...